ArticleBMC ophthalmology2015
Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment.
Article in BMC ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Beyond prevalence: diagnostic heterogeneity in population-based glaucoma studies in Africa-a systematic review.Frontiers in medicine · 2026Pooled it
- Global estimates on the number of people blind or visually impaired by glaucoma: A meta-analysis from 2000 to 2020.Eye (London, England) · 2024Pooled it
- Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial.The Lancet. Global health · 2021Trial
- West Indies Glaucoma Laser Study (WIGLS): 1. 12-Month Efficacy of Selective Laser Trabeculoplasty in Afro-Caribbeans With Glaucoma.American journal of ophthalmology · 2017Trial
- Characterizing the Modern Interventional Glaucoma Treatment Paradigm: The Newton Registry.Ophthalmology and therapy · 2026Article
- Association between alcohol and tobacco use and primary open-angle glaucoma: the Eyes of Africa study.Eye and vision (London, England) · 2026Article
- Determinants of blindness from glaucoma among patients receiving treatment: a retrospective cohort study in Enugu, Nigeria.BMC ophthalmology · 2025Article
- Glaucoma medication non-adherence rate and associated barriers among glaucoma patients in Hawassa, Ethiopia.BMC ophthalmology · 2024Article
- The financial burden of noncommunicable diseases from out-of-pocket expenditure in sub-Saharan Africa: a scoping review.Health promotion international · 2024Article
- Social determinants of health and health disparities in glaucoma: A review.Clinical & experimental ophthalmology · 2024Review
- [Global ophthalmology : Update].Die Ophthalmologie · 2024Article
- Factors limiting glaucoma care among glaucoma patients in Nigeria: A scoping review.PLOS global public health · 2024Article
- Article
- Visual Impairment and Blindness among Patients at Nigeria Army Eye Centre, Bonny Cantonment Lagos, Nigeria.Healthcare (Basel, Switzerland) · 2022Article
- Factors associated with adherence to treatment in patients with open angle glaucoma in Sierra Leone, West Africa: patient demographics and questionnaire.International ophthalmology · 2022Article
- Assessment of parasympathetic cardiovascular activity in primary open-angle glaucoma.International ophthalmology · 2022Article
- Article
- Visual field-based grading of disease severity in newly diagnosed primary open angle glaucoma patients presenting to a tertiary eye care centre in India.International ophthalmology · 2021Article
- Clinical and sociodemographic characteristics of glaucoma patients at a tertiary referral facility in Zimbabwe.Malawi medical journal : the journal of Medical Association of Malawi · 2021Article
- Prevalence of primary open-angle glaucoma in a Somalia population.International ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the stage of primary open angle glaucoma at presentation at a tertiary eye unit, to assess patient's knowledge of glaucoma and acceptance and subsequent adherence to treatment.
methodInformation collected prospectively on new glaucoma patients aged 30 or more years included distance from residence and what they knew about glaucoma and its treatment. Treatment offered took account of disease severity and socioeconomic factors. Reasons for not accepting surgery were recorded. At follow up intraocular pressure (IOP) was measured and adherence to medication assessed verbally. Four categories of severity were defined based on visual acuity and visual fields defects in the worse eye.
results131 patients were recruited (mean age 52.8 years; 62% male). Most attended because of symptoms (70%). Mean IOP in affected eyes was 31.9+/-SD 12.4 and mean vertical cup:disc ratio was 0.8. 99 eyes (47%) had a visual acuity of light perception or worse. Risk factors for advanced/end-stage disease were age >50 years, living >10 km from the hospital, some awareness of glaucoma, not being literate, being unemployed and presenting with symptoms. In multivariable analysis older age and poor knowledge of glaucoma remained independent risk factors. 75 were offered trabeculectomy: five agreed but only one underwent surgery. Reasons for rejecting surgery were fear (37%), preferred medical treatment (27 %) and cost (15 %). 32/85 (24 %) participants started on topical medication attended follow up. 72% reported excellent compliance but only 56% of glaucomatous eyes had IOPs less than 21 mmHg.
conclusionsTo prevent glaucoma blindness strategies are required which promote earlier detection, with counselling to promote acceptance of and adherence to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.